MacroGenics (MGNX) Receiving Somewhat Favorable Media Coverage, Report Finds
Headlines about MacroGenics (NASDAQ:MGNX) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MacroGenics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.8355991474273 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern’s scoring:
- MacroGenics Inc (MGNX) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- MacroGenics (MGNX) Downgraded by BidaskClub (americanbankingnews.com)
- Financial Review: MacroGenics (MGNX) and Atara Biotherapeutics (ATRA) (americanbankingnews.com)
- Incyte’s Collaborations and Developments in 4Q17 (finance.yahoo.com)
MacroGenics (MGNX) opened at $19.78 on Wednesday. The company has a market cap of $755.97, a PE ratio of -4.40 and a beta of 2.73. MacroGenics has a 12-month low of $14.36 and a 12-month high of $22.31.
Several analysts have recently weighed in on the stock. BidaskClub lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Zacks Investment Research upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Raymond James Financial reiterated a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. Finally, Citigroup lifted their target price on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. MacroGenics presently has an average rating of “Buy” and a consensus target price of $30.10.
In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the senior vice president now directly owns 35,000 shares in the company, valued at $700,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. 8.30% of the stock is owned by insiders.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Stock Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related stocks with our FREE daily email newsletter.